SAB Biotherapeutics (SABS) EBT Margin (2021 - 2024)

SAB Biotherapeutics (SABS) has 4 years of EBT Margin data on file, last reported at 8347.5% in Q4 2024.

• Quarterly EBT Margin fell 85375.0% year-over-year to 8347.5% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2441.38% (down 55688.0% YoY) and the FY2024 annual result came in at 3237.31%, down 135281.0% from the prior year.
• EBT Margin slipped to 8347.5% in Q4 2024, from 2787.69% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 9.13% in Q1 2022 to a low of 8347.5% in Q4 2024.
• A 4-year average of 1976.2% and a median of 363.23% in 2022 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2023 — EBT Margin sank 796947 bps — and 2024, when it surged 525843 bps.
• Tracing SABS's EBT Margin over 4 years: stood at 104.46% in 2021, then plunged by 248 bps to 363.23% in 2022, then plunged by 1963 bps to 7493.75% in 2023, then retreated by 11 bps to 8347.5% in 2024.
• The last three EBT Margin figures came in at 8347.5% (Q4 2024), 2787.69% (Q2 2024), and 532.06% (Q1 2024), per Business Quant data.